How to Group Multiple Models for Australia Medical Device Registration?

How to Group Multiple Models for Australia Medical Device Registration?

Grouping multiple models in a single Australia medical device registration can significantly reduce costs and timeline. Under the Australian Therapeutic Goods Regulations and TGA classification rules, manufacturers must first determine the risk class (I, IIa, IIb, III, AIMD). The key is to demonstrate essential equivalence across models in intended use, principle of operation, key performance parameters, materials, and sterilization methods, allowing sharing of technical documents such as risk management reports, clinical evaluations, and biocompatibility tests. TGA accepts the concept of families or systems, requiring a justification for grouping and a clear description of differences per model. For Class IIa and above, an Australian Sponsor is mandatory and bears post-market surveillance responsibilities. Common risks include insufficient grouping justification, incomplete difference analysis, inadequate clinical evidence coverage, and inconsistent labeling. It is recommended to map the model matrix early, complete core model technical files, and then extend coverage via difference analysis.

Applicable Scenarios and Core Questions

In the process of Australia medical device registration, companies often face whether to submit each model individually. TGA allows multiple models to be grouped under certain conditions, known as grouped submission, which can reduce fees, shorten review time, and simplify post-market changes. Typical scenarios include different specifications of the same design family (e.g., catheters of varying lengths/diameters), different configurations of the same system (e.g., imaging device components), or consumables with same intended use but different appearance/packaging. The core question is how to determine which models can be grouped and how to prepare the grouped submission dossier.

Registration Decision Logic

Determine Product Scope and Risk Class

First, confirm if the product falls under Australia’s medical device regulatory scope. Then classify risk per TGA rules: Class I (low), IIa (low-medium), IIb (medium-high), III (high), AIMD (active implantable). Grouping is generally applicable to models of the same risk class; different classes cannot be mixed unless part of a system.

Assess GMDN Code or Product Family

TGA references GHTF guidance requiring grouped models to share the same intended purpose, basic principle, key performance indicators, and sterilization method. For example, syringes of different sizes can be grouped, but different materials (e.g., PP vs. PC) usually require separate submissions.

Evaluate Existing Documentation

If NMPA, CE, FDA, or MDSAP certificates exist, consider using equivalent documentation. Ensure technical files (e.g., risk management, clinical evaluation) cover all model differences. For minor differences, a difference analysis can supplement without duplicating full files.

Confirm Sponsor Responsibilities

Each grouped submission must have one Australian Sponsor responsible for post-market surveillance, adverse event reporting, and change management. Changes to any model in the group must be notified collectively to TGA.

Required Documentation and Evidence

Grouped submission must include:

• Grouping Justification Statement: Detailed explanation why models belong together, including a list of all models and their differences.
• Difference Analysis Table: Parameter comparison of each model against the master model (usually the most complex), covering dimensions, performance, materials, packaging, etc.
• Technical Files: Risk management report (ISO 14971), clinical evaluation report, biocompatibility test report (ISO 10993), electrical safety and EMC test reports (if active). Ensure test samples cover representative models.
• Labels and Instructions for Use: Label samples for each model, with device identifier and UDI (if applicable). IFU may be shared but must note model differences.
• Quality System Certificate: Copy of ISO 13485 or MDSAP certificate.

For Class IIa and above, additionally provide: design verification and validation documents, manufacturing flow chart, sterilization validation report (if applicable), and software validation documents (if any).

Common Mistakes

• Insufficient Grouping Justification: Requesting grouping only because models are from the same series without proof of substantial equivalence. TGA may require withdrawal and splitting.
• Neglecting Difference Analysis: Copying technical files for all models without impact assessment of differences (e.g., catheter length affecting usability may require extra validation data).
• Inadequate Clinical Evidence: Using clinical data from one model to cover others without demonstrating sample representativeness. TGA may require additional clinical trials or literature.
• Unclear Sponsor Responsibilities: Sponsor for group is not the same entity or cannot take full responsibility for all models, leading to compliance gaps during changes.
• Labeling Omissions: Labels of certain models not meeting TGA requirements (e.g., missing manufacturer address, warnings), causing rejection of the entire submission.

Company Preparation Checklist

• ☐ Compile a list of all models, identify master model and variant models.
• ☐ Draft grouping justification statement, referencing GHTF/IMDRF guidelines.
• ☐ Complete difference analysis table, noting each difference’s impact on safety and effectiveness.
• ☐ Ensure technical files cover key performance parameters of all models.
• ☐ Supplement necessary validation tests for variant models (e.g., biocompatibility, mechanical performance).
• ☐ Verify quality system certificate covers manufacturing sites for all models.
• ☐ Appoint Australian Sponsor and sign authorization agreement.
• ☐ Prepare label and IFU samples in unified format.
• ☐ Conduct internal review or consult third-party regulatory advisor before submission.

AIMEILI Viewpoint

Companies often mistakenly assume that models with similar names can be grouped. TGA’s review of substantial equivalence is strict, especially regarding differences in materials, structure, or performance. We recommend early model matrix analysis to select a core model and devise validation plans for differences. For products already registered under CE, FDA, or NMPA, technical files can be reused but must be converted to TGA-required format, especially clinical evaluation conforming to Australian ethnicity and epidemiological requirements. The local Sponsor is not just a signatory but bears post-market surveillance and change management responsibilities—do not ignore their qualifications and efficiency. For multi-country registrations, it is advisable to base on core files and generate submission packages per country to avoid duplication. Grouped submission is an effective cost- and time-saver, but must be built on a rigorous evidence chain of differences.

Frequently Asked Questions (FAQ)

Q1: If new models need to be added after grouped registration, how to handle?

Adding a new model to an existing group is a change notification. Submit a change notification explaining the relationship of the new model to the existing group. If it is essentially equivalent, a simplified change procedure applies; if differences are significant, separate submission or re-grouping may be needed. It is advisable to define the group’s boundaries upfront to allow expansion.

Q2: Can products of different risk classes be in one group?

In principle, no. TGA requires all models in a group to belong to the same risk class. For example, Class IIa and IIb products cannot be mixed. If a family contains different risk classes, they must be registered separately. An exception is for systems or combination products, which require individual assessment.

Q3: Is the review timeline for grouped submission shorter than individual submissions?

In theory, TGA reviews a grouped submission similarly to a single product, but due to integrated documentation, it can often pass faster. Actual timeline depends on completeness of technical files and adequacy of grouping justification. If TGA requests additional information, all models in the group may be delayed simultaneously. Therefore, it is recommended to have a professional regulatory advisor pre-review the dossier.

Content compiled from AIMEILI registration practice database, international medical device registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country regulatory authority and product documentation.